B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

APAF1

MOLECULAR TARGET

apoptotic peptidase activating factor 1

UniProt: O14727NCBI Gene: 31717 compounds

APAF1 (apoptotic peptidase activating factor 1) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting APAF1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Methylene Blue1.393
2Cefixime1.393
3Sertraline0.691
4Aripiprazole0.691
5Astemizole Antihistamine drug now withdrawn from0.691
6Chlorhexidine0.691
7Domperidone0.691
8Edaravone0.691
9Fluspirilene0.691
10lidoflazine0.691
11ninhydrin0.691
12Perphenazine0.691
13Sphingosine0.691
14streptonigrin0.691
15Thioridazine0.691
16triflupromazine hydrochloride0.691
17Zonisamide0.691

About APAF1 as a Drug Target

APAF1 (apoptotic peptidase activating factor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented APAF1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

APAF1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.